Mahmoud Rafieian-Kopaei
1, Hamid Nasri
2*1 Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Iran
*Corresponding Author: *Corresponding author: Prof. Hamid Nasri, Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran., Email:
hamidnasri@yahoo.com
Abstract
To evaluate the immune response to hepatitis B vaccination in stable hemodialysis (HD) patients, a retro-prospective investigation was conducted on 68 HD patients. Participants were vaccinated against hepatitis B virus with an intramuscular hepatitis B vaccination schedule, 40 micrograms at 0, 1, and 6 months. The serum antibody level against hepatitis B surface antigen (HBs) in HD patients was 35±55. In this study, no significant differences of Anti-HBs antibody between diabetic and non-diabetics or male and female subjects were observed. There were not any significant correlation between antibody against HBs-Ag and serum albumin. There was not significant correlation between anti-HBs antibody and age, proportion of HD, duration of HD or dialysis efficacy. In this study, there was not significant correlation between serum antibody level against hepatitis B surface antigen and some demographic indices of HD patients, however, these findings need to re-test in other centers with more participants.
Implication for health policy/practice/research/medical education:
In a study on 68 hemodialysis participants, no significant differences of Anti-HBs antibody between diabetic and non-diabetics or male and female subjects were observed. There were not significant correlation between anti-HBs antibody and age, proportion of hemodialysis, duration of hemodialysis or hemodialysis efficacy. In this study, there was not significant correlation between serum antibody level against hepatitis B surface antigen and some demographic indices of hemodialysis patients, however, these findings need to re-test in other centers with more participants.
Please cite this paper as:
Nasri H, Rafieian-Kopaei M. Serum anti-hepatitis B surface antigen in hemodialysis patients. J Nephropharmacol 2012; 1(1): 3–5.